Medtronic on Edwards' tail with US Evolut R approval
This article was originally published in Clinica
The US FDA has approved Medtronic's second-generation transcatheter aortic valve replacement system, CoreValve Evolut R, just a week after the agency gave the green light to the company’s arch TAVR rival, Edwards Lifesciences.
You may also be interested in...
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
The Texas company is planning to sell 30,000 at-home sample collection kits for COVID-19 testing beginning on 23 March.
In this episode of our weekly podcast, Medtech Insight managing editor Marion Webb talks with deputy editor Reed Miller about her story on US hospitals canceling elective surgeries to preserve critical resources in response to COVID-19, and hospitals joining forces with medtechs to find rapid technological solutions to keep patients and caregivers healthy.